See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Natural Disasters
Social Media
Eid
Tariffs
Donald Trump
US Politics
Artificial Intelligence
Stock Markets
Education
Taxes
Senate
Baseball
Published • loading... • Updated

Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules

Summary by Gilbert Sun News
Majority of Participants Reached a Defined Threshold for Remission of Tardive Dyskinesia Regardless of Underlying Psychiatric DisorderFindings Presented at the 2025 Psychiatry Update Conference

8 Articles

All
Left
1
Center
2
Right
1
theunion.comtheunion.com
+5 Reposted by 5 other sources
Center

Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules

Majority of Participants Reached a Defined Threshold for Remission of Tardive Dyskinesia Regardless of Underlying Psychiatric DisorderFindings Presented at the 2025 Psychiatry Update Conference

Read Full Article
Pharmacy TimesPharmacy Times

48-Week Data Show Efficacy of Valbenazine in Patients With Tardive Dyskinesia and Schizophrenic, Mood Disorders

About 59.2% of patients with tardive dyskinesia (TD) who completed the 48-week trial achieved remission.

Read Full Article
psychiatrictimes.compsychiatrictimes.com

New 48-Week Remission Data on Ingrezza for the Treatment of Tardive Dyskinesia

Check out new data from the long-term, open-label KINECT 4 study on Ingrezza capsules for the treatment of tardive dyskinesia.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 50% of the sources are Center
50% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Gilbert Sun News broke the news in on Thursday, March 20, 2025.
Sources are mostly out of (0)

Similar News Topics

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal